See more : Regional S.A.B. de C.V. (RA.MX) Income Statement Analysis – Financial Results
Complete financial analysis of Sun Pharmaceutical Industries Limited (SUNPHARMA.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sun Pharmaceutical Industries Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Velan Inc. (VLNSF) Income Statement Analysis – Financial Results
- Ideal Holdings S.A. (INTEK.AT) Income Statement Analysis – Financial Results
- Conifex Timber Inc. (CFXTF) Income Statement Analysis – Financial Results
- Stelar Metals Limited (SLB.AX) Income Statement Analysis – Financial Results
- Thai Energy Storage Technology Public Company Limited (3K-BAT.BK) Income Statement Analysis – Financial Results
Sun Pharmaceutical Industries Limited (SUNPHARMA.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.sunpharma.com
About Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and anti retro viral medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 477.58B | 432.79B | 384.26B | 332.33B | 323.25B | 286.86B | 260.65B | 299.94B | 274.98B | 272.45B | 160.04B | 112.36B | 80.01B | 57.28B | 38.09B | 42.72B | 33.57B | 21.36B | 16.37B | 11.85B | 9.85B |
| Cost of Revenue | 248.12B | 106.62B | 103.52B | 98.85B | 104.71B | 92.39B | 88.26B | 94.25B | 73.34B | 77.76B | 33.78B | 25.34B | 19.82B | 17.13B | 10.98B | 8.56B | 7.22B | 5.77B | 4.88B | 3.22B | 2.39B |
| Gross Profit | 229.46B | 326.17B | 280.75B | 233.48B | 218.54B | 194.48B | 172.39B | 205.70B | 201.64B | 194.69B | 126.27B | 87.02B | 60.19B | 40.15B | 27.11B | 34.17B | 26.34B | 15.59B | 11.49B | 8.63B | 7.46B |
| Gross Profit Ratio | 48.05% | 75.36% | 73.06% | 70.25% | 67.61% | 67.79% | 66.14% | 68.58% | 73.33% | 71.46% | 78.90% | 77.45% | 75.23% | 70.10% | 71.18% | 79.97% | 78.48% | 72.98% | 70.17% | 72.82% | 75.77% |
| Research & Development | 31.28B | 22.26B | 21.23B | 20.97B | 19.25B | 19.06B | 20.52B | 21.46B | 22.24B | 18.37B | 9.86B | 6.62B | 0.00 | 2.86B | 2.08B | 3.10B | 2.73B | 2.44B | 1.53B | 1.01B | 0.00 |
| General & Administrative | 34.37B | 28.18B | 21.87B | 23.85B | 22.28B | 16.96B | 18.46B | 16.67B | 21.15B | 18.69B | 5.71B | 4.79B | 3.56B | 2.87B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 57.80B | 52.26B | 32.82B | 24.82B | 30.82B | 21.06B | 15.01B | 21.87B | 18.73B | 26.80B | 16.07B | 9.31B | 6.85B | 4.90B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 92.17B | 79.69B | 54.69B | 48.67B | 53.10B | 38.02B | 33.48B | 38.54B | 39.88B | 45.49B | 21.78B | 14.10B | 10.40B | 7.78B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 6.35B | 9.22B | 570.20M | 1.13B | 1.48B | 894.80M | 574.90M | 574.50M | 1.17B | 915.60M | 631.60M | 433.20M | 659.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 356.89B | 233.73B | 199.75B | 169.21B | 169.18B | 147.23B | 131.52B | 120.23B | 126.49B | 126.15B | 58.82B | 40.96B | 30.49B | 22.74B | 12.96B | 14.68B | 10.35B | 7.25B | 5.52B | 4.42B | 3.65B |
| Cost & Expenses | 383.35B | 340.35B | 303.26B | 268.07B | 273.90B | 239.62B | 219.78B | 214.47B | 199.84B | 203.91B | 92.59B | 66.30B | 50.31B | 39.86B | 23.94B | 23.23B | 17.57B | 13.02B | 10.40B | 7.64B | 6.03B |
| Interest Income | 10.23B | 3.42B | 5.53B | 2.11B | 3.55B | 6.69B | 5.20B | 3.71B | 3.57B | 2.57B | 2.06B | 2.37B | 1.98B | 2.23B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.38B | 1.72B | 1.27B | 1.41B | 2.91B | 5.25B | 4.52B | 3.30B | 3.03B | 3.01B | 199.60M | 368.90M | 282.00M | 738.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 25.57B | 25.29B | 21.44B | 20.80B | 20.53B | 17.53B | 15.00B | 12.65B | 10.38B | 11.95B | 4.09B | 3.36B | 2.91B | 2.05B | 1.53B | 1.23B | 968.60M | 813.30M | 610.20M | 406.00M | 285.70M |
| EBITDA | 138.36B | 120.85B | 67.00B | 49.99B | 73.13B | 60.84B | 54.04B | 106.73B | 80.78B | 81.77B | 50.37B | 46.95B | 36.76B | 23.18B | 15.68B | 20.72B | 16.96B | 9.15B | 6.58B | 4.62B | 4.10B |
| EBITDA Ratio | 28.97% | 28.38% | 29.46% | 27.24% | 23.25% | 25.08% | 23.63% | 35.36% | 30.93% | 29.93% | 47.04% | 46.92% | 46.01% | 40.45% | 41.17% | 48.51% | 50.54% | 42.83% | 40.20% | 38.94% | 41.62% |
| Operating Income | 104.68B | 91.11B | 81.26B | 64.99B | 52.40B | 49.22B | 41.10B | 84.88B | 75.14B | 69.61B | 71.19B | 49.36B | 33.90B | 21.12B | 14.15B | 19.49B | 15.99B | 8.33B | 5.97B | 4.21B | 3.81B |
| Operating Income Ratio | 21.92% | 21.05% | 21.15% | 19.56% | 16.21% | 17.16% | 15.77% | 28.30% | 27.33% | 25.55% | 44.48% | 43.93% | 42.37% | 36.88% | 37.15% | 45.62% | 47.65% | 39.02% | 36.47% | 35.51% | 38.72% |
| Total Other Income/Expenses | 6.20B | 1.31B | -36.19B | -36.15B | -2.30B | -9.08B | -5.91B | 5.63B | -9.26B | -4.21B | -21.63B | -2.84B | -333.80M | -730.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 110.88B | 94.08B | 44.81B | 27.99B | 50.10B | 38.10B | 34.79B | 90.48B | 65.71B | 64.03B | 45.81B | 43.21B | 33.56B | 20.39B | 14.15B | 19.49B | 15.99B | 8.33B | 5.97B | 4.21B | 3.81B |
| Income Before Tax Ratio | 23.22% | 21.74% | 11.66% | 8.42% | 15.50% | 13.28% | 13.35% | 30.17% | 23.89% | 23.50% | 28.62% | 38.46% | 41.95% | 35.60% | 37.15% | 45.62% | 47.65% | 39.02% | 36.47% | 35.51% | 38.72% |
| Income Tax Expense | 14.39B | 8.48B | 10.76B | 5.15B | 8.23B | 6.01B | 9.11B | 12.12B | 9.14B | 9.15B | 7.02B | 8.46B | 3.13B | 1.29B | 678.60M | 711.60M | 484.80M | -66.80M | 239.30M | 204.80M | 554.00M |
| Net Income | 95.76B | 84.74B | 32.73B | 29.04B | 37.65B | 26.65B | 20.96B | 69.64B | 45.46B | 45.39B | 31.41B | 29.83B | 26.57B | 18.16B | 13.47B | 18.78B | 15.51B | 8.40B | 5.73B | 4.00B | 3.31B |
| Net Income Ratio | 20.05% | 19.58% | 8.52% | 8.74% | 11.65% | 9.29% | 8.04% | 23.22% | 16.53% | 16.66% | 19.63% | 26.55% | 33.20% | 31.71% | 35.37% | 43.96% | 46.21% | 39.33% | 35.01% | 33.78% | 33.60% |
| EPS | 39.90 | 35.32 | 13.64 | 12.10 | 15.69 | 11.08 | 8.73 | 29.00 | 18.90 | 18.90 | 15.20 | 14.40 | 12.85 | 8.75 | 6.50 | 8.78 | 7.47 | 4.17 | 3.09 | 2.14 | 3.54 |
| EPS Diluted | 39.91 | 35.32 | 13.64 | 12.10 | 15.69 | 11.08 | 8.73 | 29.00 | 18.90 | 18.90 | 15.20 | 14.40 | 12.85 | 8.75 | 6.50 | 8.78 | 7.18 | 3.89 | 2.77 | 2.08 | 1.77 |
| Weighted Avg Shares Out | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.41B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B |
| Weighted Avg Shares Out (Dil) | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.41B | 2.41B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B |
Source: https://incomestatements.info
Category: Stock Reports